Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cary Fishburne

Urogynecology and Reconstructive Pelvic Surgery Charlotte, NC Medical Doctor

NPI 1285624031 CMS profile 285255

10220 Prosperity Park Dr Ste 300, Ste 102, Charlotte, NC 28269

Open in the dashboard

General payments

$230,751

521 records reported · program years 2019–2025

Research payments

$315

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cary Fishburne of Charlotte, NC is reported in the CMS Open Payments database as having received $230,751 across 521 general payments and $315 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Urogynecology and Reconstructive Pelvic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $75,326 152
2024 General $36,089 71
2023 General $27,647 71
2022 General $68,601 124
2021 General $20,060 43
2021 Research $315 1
2020 General $1,340 14
2019 General $1,687 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cary Fishburne
  • Urogynecology and Reconstructive Pelvic Surgery median
  • Middle half of Urogynecology and Reconstructive Pelvic Surgery
  • National median

In program year 2025, general payments to Cary Fishburne were reported at $75,326. Among 802 Urogynecology and Reconstructive Pelvic Surgery profiles paid that year, the median was $412 and the middle half received between $133 and $1,300.

Show as a table
Year Cary Fishburne Urogynecology and Reconstructive Pelvic Surgery median Middle half National median
2019 $1,687 $358 $132–$1,270 $163
2020 $1,340 $198 $86–$642 $114
2021 $20,060 $361 $118–$1,182 $132
2022 $68,601 $410 $128–$1,175 $149
2023 $27,647 $434 $152–$1,344 $160
2024 $36,089 $494 $193–$1,331 $164
2025 $75,326 $412 $133–$1,300 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $224,908 397 payments
  2. Medtronic USA, Inc. $1,735 15 payments
  3. Coloplast Corp $1,085 31 payments
  4. Valencia Technologies Corporation $686 4 payments
  5. Boston Scientific Corporation $622 10 payments
  6. Astellas Pharma US Inc $392 12 payments
  7. Axonics Modulation Technologies, Inc. $327 9 payments
  8. Caldera Medical, Inc $212 3 payments
  9. AbbVie, Inc. $184 13 payments
  10. Abbott Laboratories $134 5 payments
  11. Other $468 22 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $178,738 51 payments
  2. Travel and Lodging $27,074 178 payments
  3. Consulting Fee $13,741 15 payments
  4. Food and Beverage $10,819 272 payments
  5. Education $353 4 payments
  6. Gift $27 1 payment
Products named General payments · program years 2019–2025
  1. INTERSTIM Sacral Nerve Stimulation $191,484 330 payments
  2. ALTAVIVA $20,057 26 payments
  3. INTERSTIM Sacral Nerve Stimulation $1,435 11 payments
  4. eCoin Device Kit $686 4 payments
  5. Altis $426 9 payments
  6. Solyx SIS System $338 4 payments
  7. AXIS $327 6 payments
  8. INTERSTIM ICON $301 4 payments
  9. Desara $212 3 payments
  10. OSTEOCOOL RF ABLATION SYSTEM $169 1 payment
  11. Other $2,030 88 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $315 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 21 drugs

Part D claims

784

Median for Obstetrics & Gynecology: 65

Drug cost

$173,100

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

61.6%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 155 $102,892
Gemtesa Vibegron Brand 40 $26,673
Mirabegron Er Mirabegron Brand 33 $17,481
Premarin Estrogens, Conjugated Brand 25 $10,988
Estradiol Generic 58 $4,064
Trospium Chloride Er Trospium Chloride Brand 25 $2,514
Trospium Chloride Generic 35 $2,132
Methenamine Hippurate Generic 16 $1,475
Desmopressin Acetate Generic 32 $1,279
Tolterodine Tartrate Er Tolterodine Tartrate Brand 15 $1,225

The 10 drugs with the highest cost, of 21 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 61 billing codes

Paid by Medicare

$163,724

Of which drugs: $17,269

Medicare patients

297

Average age 75

Services billed

5,555

297 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 63%
Depression 31%
Osteoporosis 27%
Diabetes 25%
Ischemic heart disease 21%
Chronic kidney disease 21%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 15 3,500 $17,082
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 15 128 $98

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $30
$30 40 —
DUAVEE
  • PFIZER INC. $15
$15 — —
PREMARIN
  • PFIZER INC. $15
$15 25 —
ESTRING
  • PFIZER INC. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

522 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urogynecology and Reconstructive Pelvic Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record